PI
RCKT icon

PFG Investments’s Rocket Pharmaceuticals RCKT Stock Holding History

PFG Investments’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,700
Closed -$34.9K – 1205
2025
Q3 		$34.9K Sell
10,700
-7,400
-41% -$23.3K ﹤0.01% 1092
2025
Q2 		$44.3K Buy
18,100
+4,700
+35% +$23.8K ﹤0.01% 1009
2025
Q1 		$89.4K Buy
+13,400
New +$132K 0.01% 943

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

PFG Investments's RCKT Position: Q4 2025 in Review

PFG Investments sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 10,700 shares — an estimated $34.9K sold.

PFG Investments first reported a position in RCKT in Q1 2025 and held it in 3 quarters. The position peaked at $89.4K in Q1 2025. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

  • PFG Investments reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PFG Investments sold 10,700 Rocket Pharmaceuticals shares in Q4 2025, an estimated $34.9K.
  • PFG Investments first reported a position in Rocket Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • PFG Investments's Rocket Pharmaceuticals position peaked at $89.4K in Q1 2025.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on PFG Investments's 13F filing for Q4 2025, filed 26 Jan 2026.